Ravi Ramjeesingh

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Thomas Arnason · 4 shared papers, 2024–2026 · strength 1.13
   • Paper Glypican-3 and Cytokeratin-19 Expression in Pancreatic Cancer in a Canadian Population. DOI 10.3390/jcm13226893↗
   • Paper Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker … DOI 10.1016/j.tranon.2025.102362↗
   • Paper Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma. DOI 10.3390/curroncol33020088↗
2. Jennifer Jane Knox · 7 shared papers, 2021–2026 · strength 1.06
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
3. Mustapha Ali Tehfe · 6 shared papers, 2022–2026 · strength 0.94
   • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
4. Boris Gala-López · 4 shared papers, 2024–2026 · strength 0.93
   • Paper Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker … DOI 10.1016/j.tranon.2025.102362↗
   • Paper Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma. DOI 10.3390/curroncol33020088↗
   • Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
5. George Zogopoulos · 6 shared papers, 2021–2026 · strength 0.89
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. DOI 10.3390/curroncol31100461↗
   • Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
6. Carley Bekkers · 3 shared papers, 2024–2025 · strength 0.87
   • Paper Glypican-3 and Cytokeratin-19 Expression in Pancreatic Cancer in a Canadian Population. DOI 10.3390/jcm13226893↗
   • Paper Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker … DOI 10.1016/j.tranon.2025.102362↗
   • Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
7. Thomas Samson · 3 shared papers, 2025–2026 · strength 0.77
   • Paper Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker … DOI 10.1016/j.tranon.2025.102362↗
   • Paper Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma. DOI 10.3390/curroncol33020088↗
   • Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
8. Steve Gallinger · 5 shared papers, 2021–2026 · strength 0.73
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
   • Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
9. Faiyaz Notta · 5 shared papers, 2021–2026 · strength 0.73
   • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
   • Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
   • Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
10. Sharlene Gill · 4 shared papers, 2022–2026 · strength 0.70
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. DOI 10.3390/curroncol31100461↗
11. Christina Kim · 4 shared papers, 2022–2026 · strength 0.70
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. DOI 10.3390/curroncol31100461↗
12. Riley J. Arseneau · 3 shared papers, 2024–2025 · strength 0.67
    • Paper Claudin 18 (43-14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker … DOI 10.1016/j.tranon.2025.102362↗
    • Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
    • Paper Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. DOI 10.3390/curroncol31100461↗
13. Chloe Cyr · 2 shared papers, 2024–2026 · strength 0.55
    • Paper Exploring patient perspectives of exercise in advanced pancreatic cancer care in Canada: A qualitative interpretive des… DOI 10.1017/s1478951526103356↗
    • Paper Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. DOI 10.3390/curroncol31100461↗
14. Petr Kavan · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
15. James Thomas Topham · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
16. Derek J. Jonker · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
17. David F. Schaeffer · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
18. Daniel John Renouf · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
19. Chris J. O’Callaghan · 3 shared papers, 2022–2026 · strength 0.54
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
    • Paper The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial t… DOI 10.1038/s41467-022-32591-8↗
20. Robert C. Grant · 4 shared papers, 2021–2025 · strength 0.52
    • Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
    • Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
    • Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
21. Grainne Mary O'Kane · 4 shared papers, 2021–2025 · strength 0.52
    • Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
    • Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
    • Paper Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospectiv… DOI 10.1016/j.ctrv.2021.102310↗
22. Jeanette E. Boudreau · 2 shared papers, 2025–2026 · strength 0.50
    • Paper Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma. DOI 10.3390/curroncol33020088↗
    • Paper Peri-tumoural lymphocyte neighbourhoods predict longer survival in pancreatic ductal adenocarcinoma. DOI 10.3389/fimmu.2025.1730817↗
23. Joanna M. Karasinska · 2 shared papers, 2026 · strength 0.42
    • Paper DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab i… DOI 10.1038/s41467-026-70120-z↗
    • Paper Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarc… DOI 10.1158/1078-0432.ccr-26-0793↗
24. Sharon E. Clarke · 2 shared papers, 2021–2026 · strength 0.42
    • Paper Preoperative Soluble AXL in Plasma Predicts Futility of Resecting Pancreatic Ductal Adenocarcinoma. DOI 10.3390/curroncol33020088↗
    • Paper The implications of missed or misinterpreted cases of pancreatic ductal adenocarcinoma on imaging: a multi-centered pop… DOI 10.1007/s00330-020-07120-0↗
25. Sandra Elisabeth Fischer · 3 shared papers, 2022–2025 · strength 0.40
    • Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
    • Paper Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. DOI 10.1038/s41416-023-02214-0↗
    • Paper hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-22-2576↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.